Improving Outcomes and Mitigating Costs Associated With CAR T-Cell Therapy
Improving Outcomes and Mitigating Costs Associated With CAR T-Cell Therapy (AJMC).
Since the historic approval of tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia in 2017, chimeric antigen receptor (CAR) T-cell therapies have altered the treatment paradigm for hematologic malignancies. Five CAR T-cell products are now approved by the US Food and Drug Administration for a growing number of cancer indications and a global market
worth billions is anticipated in the next 5 years.
[...]
In the meantime, payers and providers are tasked with facing the
logistical complexities of CAR T-cell therapy and developing new payment and
reimbursement strategies to ensure value-based care and optimal access today.
Quelle: AJMC, 18.08.2021
